Gene Biotherapeutics Inc.
PrivateLast Round
Series B
May 22, 2020
Est. Valuation
$20M
Total Funding Raised
$10.25M
Company Overview
Gene Biotherapeutics Inc. is a clinical-stage biotechnology company that develops and commercializes DNA-based biotherapeutics for the treatment of cardiovascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gene Biotherapeutics Inc. Comparables
Compare Gene Biotherapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XyloCor Therapeutics | 91% | |
| Renova Therapeutics | 81% | |
| AnGes, Inc. | 65% | |
Gene Biotherapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 22, 2020 | ||||
| Series A | Jun 7, 2016 | ||||
| Strategic | Mar 3, 2014 | ||||
| Series A | Apr 4, 2013 | ||||
| Private Placement | Feb 16, 2012 | ||||
Private Placement | Oct 15, 2009 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 16, 2012
$5M round completed.
Gene Biotherapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Gene Biotherapeutics Inc.'s valuation, stock price, and market status.